DOCSLIB.ORG

Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….…… DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……......... 284 PART II. COMMERCIAL INFORMATION Pharmaceuticals (trade names) …………………………………...……………… 319 INDEXES A. Index by Chemical Abstract Service (CAS) Registry numbers ……….……. 415 B. Index to Pharmaceuticals by scientific and common names, and synonyms…. 432 C. Index to Pharmaceuticals by available trade names ….………………..…....…465 ANNEXES I. Relevant resolutions of the General Assembly and Economic and Social Council ……………………………………………………......…… 559 II. Criteria for the inclusion of pharmaceutical and chemical products in the Consolidated List ……………………………………... ……..…...… 573 III. List of references cited in the regulatory text………..…. ……………….… 574 IV. Questionnaire ……………………………………………………...…….…… 595 ALPHABETICAL LISTING OF PRODUCTS Product name Page Acarbose............................................................................................................................................................ 31 ACE-Inhibitors.................................................................................................................................................... 284 Acetanilide.......................................................................................................................................................... 31, 319 Acetarsol............................................................................................................................................................ 31, 319 Acetylfuratrizine.................................................................................................................................................. 32, 319 Acetylleucine...................................................................................................................................................... 32 Acetylsalicylic acid (paediatric).......................................................................................................................... 32, 319 Acetylsalicylic acid/antacid................................................................................................................................. 285 Acetylsalicylic acid/codeine................................................................................................................................ 285 Acetylsalicylic acid/phenacetin/caffeine (APC).................................................................................................. 285 Acitretin.............................................................................................................................................................. 35, 319 Acridine derivatives............................................................................................................................................ 36, 320 Alatrofloxacin mesilate....................................................................................................................................... 37 Albumin.............................................................................................................................................................. 37 Alclofenac........................................................................................................................................................... 38, 320 Aldesleukin......................................................................................................................................................... 39 Allergen extracts................................................................................................................................................. 39, 320 Allopurinol and benzbromarone......................................................................................................................... 286 Almitrine............................................................................................................................................................. 39 Aloxiprin.............................................................................................................................................................. 40, 320 Alpidem.............................................................................................................................................................. 40 Alprostadil........................................................................................................................................................... 40, 320, 321 Amaranth............................................................................................................................................................ 41 Amfepramone hydrochloride.............................................................................................................................. 42 Amfepramone..................................................................................................................................................... 42, 321 Amfetamine........................................................................................................................................................ 42, 321 Amineptine......................................................................................................................................................... 43 Aminoglutethimide.............................................................................................................................................. 44, 322 Aminophenazone............................................................................................................................................... 44, 322, 323 Aminophylline..................................................................................................................................................... 47, 323 Aminorex............................................................................................................................................................ 47, 323 Amiprilose........................................................................................................................................................... 48 Amitriptyline........................................................................................................................................................ 48, 324 Amobarbital........................................................................................................................................................ 49, 324, 325 Amodiaquine...................................................................................................................................................... 49, 325 Amoxicillin/clavulanic acid.................................................................................................................................. 286 Ampicillin/cloxacillin............................................................................................................................................ 286, 325 Amyl nitrite.......................................................................................................................................................... 50 Anabolic steroids................................................................................................................................................ 50 Anagestone acetate........................................................................................................................................... 50 Analgesics in combination................................................................................................................................
Load more

Recommended publications
  • Alzheimer's Disease, a Decade of Treatment: What Have We Learned?
    A Critical Look at Medication Dementia: Alzheimer’s Disease Management Issues in Alzheimer’s Disease R.Ron Finley, B.S. Pharm., R.Ph,CGP Lecturer (Emeritus) and Assistant Clinical Professor, UCSF School of Pharmacy Clinical Pharmacist, UCSF Memory and Aging Center- Alzheimer’s Research Center Educational Objectives Disclosures 1. Define the role for cholinesterase inhibitors in the management of Alzheimer’s disease, Lewy Body dementia, Frontal Temporal Lobe dementia. Pfizer Speakers Bureau 2. Name three common side effects of atypical antipsychotic Forest Speakers Bureau drugs. Novartis Speakers Bureau 3. Construct a pharmacological treatment plan for a 77-year-old Rx Consultant Associate Editor patient diagnosed with Alzheimer’s disease and hallucinations. WindChime Consultant 4. Describe the role for antipsychotic, antidepressant, mood HGA HealthCare Consultant stabilizers and benzodiazepines in the management of psychiatric behavior problems related to Alzheimer’s disease. Elder Care Specialist Consultant 5. Cite three potential drug or disease interactions with cholinesterase inhibitors. The Many Faces of Dementia Risk Factors Linked to AD Alzheimer’s Disease Over 65 years of age and increases Vascular: Multi-infarct with age FrontalTemporal Lobe dementia ( FTD) and female Pick’s disease Head injury Lewy Body Dementia Progressive Supranuclear Palsy Factors associated with DM, HTN, CVD Corticobasal Degeneration Genetic: family history, specific Primary Progressive Aphasia chromosome mutations Huntington’s disease
    [Show full text]
  • Meprobamate Art 107 AR
    30 March 2012 EMA/212617/2012 Assessment report for meprobamate-containing medicinal products for oral use Procedure number: EMEA/H/A-107/1316 Procedure under Article 107 of Directive 2001/83/EC, as amended Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7051 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2012. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 3 1.1. Referral of the matter to the CHMP ......................................................................... 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Discussion on safety ............................................................................................. 4 2.2.1. Non-clinical data ................................................................................................ 4 2.2.2. Clinical safety .................................................................................................... 4 2.2.2.1. Clinical studies ..............................................................................................
    [Show full text]
  • Automated Annotation of Structurally Uncharacterized Metabolites in Human Metabolomics Studies by Systems Biology Models
    Technische Universität München Automated annotation of structurally uncharacterized metabolites in human metabolomics studies by systems biology models Jan-Dominik Bernd Quell 2019 Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt Technische Universität München Lehrstuhl für Experimentelle Bioinformatik Automated annotation of structurally uncharacterized metabo- lites in human metabolomics studies by systems biology models Jan-Dominik Bernd Quell Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Er- nährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) genehmigten Dissertation. Vorsitzender: Prof. Dr. Dmitrij Frischmann Prüfer der Dissertation: 1. Prof. Dr. Hans-Werner Mewes 2. Prof. Dr. Bernhard Küster Die Dissertation wurde am 28.11.2018 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 28.01.2019 angenommen. „Der Mensch muß bei dem Glauben verharren, daß das Unbegreifliche begreiflich sei; er würde sonst nicht forschen.“ Johann Wolfgang von Goethe i Danksagung Zunächst möchte ich mich ganz besonders bei meinem Doktorvater (Hans-)Werner Mewes bedanken, der mir nicht nur die Möglichkeit gegeben hat an seinem Institut des Helmholtz Zentrums München sowie seinem Lehrstuhl an der Technischen Uni- versität München in Forschung und Lehre zu arbeiten, sondern auch meine Laufbahn
    [Show full text]
  • Synthetic Drugs
    Comprehensive and Confident Identification of Narcotics, Steroids and Pharmaceuticals in Urine David E. Alonso1, Petra Gerhards2, Charles Lyle1 and Joe Binkley1 | 1LECO Corporation, St. Joseph, MI; 2LECO European LSCA Centre, Moenchengladbach, Germany Introduction Experimental Sample A (Traditional Drugs) Sample B (Synthetic Drugs) Monitoring of patients in hospitals and clinics has traditionally relied on Samples Representative Compounds Representative Compounds targeted methods of analysis. These screening methods are not Peak # Name Formula R.T. (s) Area Similarity Mass Delta (mDa) MA (ppm) 1 Creatinine ME C5H9N3O 210 1326229 800 -0.05 -0.43 • Obtained from a collaborating European hospital 3.5e6 3.0e6 Peak # Name Formula R.T. (s) Area Similarity 2 o-Ethynylaniline C8H7N 219 167436 893 0.07 0.63 1 Indole C8H7N 213 2744171 917 comprehensive and result in an incomplete picture of a patient’s 3 2-Methoxy-4-vinylphenol C H O 223 65764 805 0.11 0.73 52 patient monitoring samples 9 10 2 2 Creatinine ME C5H9N3O 216 613318 651 • 2.5e6 4 Nicotine C10H14N2 234 3249121 898 -0.21 -1.29 3 Pyridine, 2-(1-methyl-2-pyrrolidinyl)- C10H14N2 230 24869771 899 activities. Gas chromatography high resolution time-of-flight mass 3.0e6 5 Hordenin C10H15NO 274 949734 775 -0.14 -0.84 4 Parabanic acid, 1-methyl- C4H4N2O3 233 434278 764 Sample preparation 5 Cotinine C10H12N2O 336 27810908 918 • 6 Methylecgonine C10H17NO3 276 104640 835 -0.22 -1.1 spectrometry (GC-HRT) provides a fast and convenient method for 2.0e6 5 6 Caffeine C8H10N4O2 371 3753598 797 2.5e6 7 4-(3-Pyridyl-tetrahydrofuran-2-one C9H9NO2 313 93817 849 -0.11 -0.68 3,4 7 1-methyl-7H-xanthine C6H6N4O2 437 4868196 850 analysis of urine samples.
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Title Effects of N-Acetyl-Leucine and Its Enantiomers in Niemann-Pick
    bioRxiv preprint doi: https://doi.org/10.1101/826222; this version posted October 31, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title Effects of N-Acetyl-Leucine and its enantiomers in Niemann-Pick disease type C cells Danielle te Vruchte1, Anthony Galione2, Michael Strupp3 and Michiko Mann1 1IntraBio Ltd, Oxford University Begbroke Science Park, Woodstock Road, Oxford, UK 2Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, UK 3Department of Neurology and German Center for Vertigo and Balance Disorders, Ludwig Maximilians University, Munich, Germany Corresponding author Danielle te Vruchte Email: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/826222; this version posted October 31, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Conflicts of Interest A.G. is a cofounder, shareholder and consultant to IntraBio. M.Y-M and D.t.V. are shareholders in IntraBio. M.S. acts as a consultant for Abbott, Actelion, AurisMedical, Heel, IntraBio and Sensorion, is a shareholder of IntraBio and Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. M.S. has received speaker’s honoraria from Abbott, Actelion, Auris Medical, Biogen, Eisai, Grunenthal, GSK, Henning Pharma, Interacoustics, Merck, MSD, Otometrics, Pierre-Fabre, TEVA, UCB. bioRxiv preprint doi: https://doi.org/10.1101/826222; this version posted October 31, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • Characterising the Risk of Major Bleeding in Patients With
    EU PE&PV Research Network under the Framework Service Contract (nr. EMA/2015/27/PH) Study Protocol Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU Version 3.0 1 June 2018 EU PAS Register No: 16014 EMA/2015/27/PH EUPAS16014 Version 3.0 1 June 2018 1 TABLE OF CONTENTS 1 Title ........................................................................................................................................... 5 2 Marketing authorization holder ................................................................................................. 5 3 Responsible parties ................................................................................................................... 5 4 Abstract ..................................................................................................................................... 6 5 Amendments and updates ......................................................................................................... 7 6 Milestones ................................................................................................................................. 8 7 Rationale and background ......................................................................................................... 9 8 Research question and objectives .............................................................................................. 9 9 Research methods ....................................................................................................................
    [Show full text]
  • Why Some Migration Conditions for Plastics Are Not Appropriate for Other Fcms
    Why some migration conditions for plastics are not appropriate for other FCMs. Peter Oldring Representing 18 associations directly or indirectly involved in FCMs FIP Network 25th May 2016 Parma 1 Extract from Executive Summary (p9) European Parliament report on 1935/2004 (May 2016) ‘As a general trend, stakeholders who are in favour of further EU level harmonisation recommend that EU specific measures should establish a single standard for analytical (testing) methods, such as composition determination, migration testing, risk assessment, but also specific methods for compliance enforcement, thus ensuring that the relevant FCM is tested by companies and competent authorities across the EU with one and the same method. Furthermore, the EU single standard for analytical (testing) methods should be specific for each FCM, thus reflecting its unique properties and avoiding situations where non-harmonised FCMs are tested with methods developed for harmonised FCMs, which could lead to misleading and debatable test results’ 2 DISCLAIMER . As chair of the 18 associations representing non- plastics, I will try and represent them. The initiative started with CEPE, EMPAC and almost immediately CES silicones joined. Other associations have joined since then. However, I have to understand and work with analytical data, in order to make decisions about and determine the safety of my company’s products. The work is embryonic, associations are still joining and the final format will certainly be different to that initially envisaged. 3 Associations participating in Initiative . ACE Beverage cartons – paper, plastics and aluminium flexible . APEAL Steel for rigid metal packaging . CEFIC-FCA Substance suppliers . CELIEGE Cork . CEPE Coatings for rigid metal packaging .
    [Show full text]
  • Withdrawing Benzodiazepines in Primary Care
    PC\/ICU/ ADTiriC • CNS Drugs 2009,-23(1): 19-34 KtVltW MKIIWLC 1172-7047/I»/O(X)1«119/S4W5/C1 © 2009 Adis Dato Intocmation BV. All rights reserved. Withdrawing Benzodiazepines in Primary Care Malcolm Luder} Andre Tylee^ and ]ohn Donoghue^ 1 Institute of Psychiatry, King's College London, London, England 2 John Moores University, Liverpool, Scotland Contents Abstract ' 19 1. Benzodiazepine Usage 22 2. Interventions 23 2.1 Simple interventions 23 2.2 Piiarmacoiogicai interventions 25 2.3 Psychoiogical Interventions 26 2.4 Meta-Anaiysis ot Various interventions 27 3. Outcomes 28 4. Practicai Issues 29 5. Otiier Medications 30 5.1 Antidepressants 30 5.2 Symptomatic Treatments 30 6. Conciusions 31 Abstract The use of benzodiazepine anxiolytics and hypnotics continues to excite controversy. Views differ from expert to expert and from country to country as to the extent of the problem, or even whether long-term benzodiazepine use actually constitutes a problem. The adverse effects of these drugs have been extensively documented and their effectiveness is being increasingly questioned. Discontinua- tion is usually beneficial as it is followed by improved psychomotor and cognitive functioning, particularly in the elderly. The potential for dependence and addic- tion have also become more apparent. The licensing of SSRIs for anxiety disorders has widened the prescdbers' therapeutic choices (although this group of medications also have their own adverse effects). Melatonin agonists show promise in some forms of insomnia. Accordingly, it is now even more imperative that long-term benzodiazepine users be reviewed with respect to possible discon- tinuation. Strategies for discontinuation start with primary-care practitioners, who are still the main prescdbers.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]